Table 1 Characteristics of participants and total respondents
From: Effects of morbidity on smoking cessation: a national smoking cessation program
Participants (N = 1245) | Total respondents (N = 1500) | p-valuea | |
|---|---|---|---|
Sex | 0.342 | ||
Male | 1118 (89.80) | 1330 (88.67) | |
Female | 127 (10.20) | 170 (11.33) | |
Age in years | |||
Mean ± SD | 48.50 ± 12.55 | 48.90 ± 12.58 | 0.416 |
< 50 | 647 (51.97) | 762 (50.80) | 0.542 |
≥ 50 | 598 (48.03) | 738 (49.20) | |
Income level | 0.921 | ||
MHI group | 1084 (87.07) | 1238 (86.94) | |
LI group | 161 (12.93) | 186 (13.06) | |
Region | 0.689 | ||
Seoul and metropolitan areas | 642 (51.57) | 762 (50.80) | |
Non-metropolitan areas | 603 (48.43) | 738 (49.20) | |
Health care facility type | 0.693 | ||
Community clinics | 946 (75.98) | 1130 (75.33) | |
Others | 299 (24.02) | 370 (24.67) | |
Program completion status | 0.371 | ||
Incomplete | 767 (61.61) | 949 (63.27) | |
Complete | 478 (38.39) | 551 (36.73) | |
Nicotine dependence levelb,c | 0.974 | ||
Light/moderate | 832 (66.83) | 907 (66.89) | |
Severe | 413 (33.17) | 449 (33.11) | |
Duration of smoking, yearsc | 25.91 ± 11.81 | 26.10 ± 11.84 | 0.691 |
Smoking cessation medicationc | 0.941 | ||
Varenicline only | 1101 (88.43) | 1307 (87.90) | |
Bupropion only | 96 (7.71) | 118 (7.94) | |
NRT only | 13 (1.04) | 19 (1.28) | |
Others | 35 (2.81) | 43 (2.89) | |
Duration of smoking cessation (months) | 0.504 | ||
< 6 | 688 (55.26) | 848 (56.53) | |
≥ 6 | 557 (44.74) | 652 (43.47) | |
Disease | |||
HTN | 241 (19.36) | 283 (18.87) | 0.745 |
DM | 154 (12.37) | 170 (11.33) | 0.402 |
DL | 95 (7.63) | 109 (7.27) | 0.717 |
No. of CVD | 0.875 | ||
0 | 830 (66.67) | 1021 (68.07) | |
1 | 345 (27.71) | 401 (26.73) | |
2 | 65 (5.22) | 73 (4.87) | |
3 | 5 (0.40) | 5 (0.33) | |
COPD | 64 (5.14) | 71 (4.73) | 0.623 |
MDD | 45 (3.61) | 49 (3.27) | 0.618 |